BRPI0918431A2 - produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista de beta-2-adrenoceptor. - Google Patents

produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista de beta-2-adrenoceptor.

Info

Publication number
BRPI0918431A2
BRPI0918431A2 BRPI0918431A BRPI0918431A BRPI0918431A2 BR PI0918431 A2 BRPI0918431 A2 BR PI0918431A2 BR PI0918431 A BRPI0918431 A BR PI0918431A BR PI0918431 A BRPI0918431 A BR PI0918431A BR PI0918431 A2 BRPI0918431 A2 BR PI0918431A2
Authority
BR
Brazil
Prior art keywords
beta
receptor antagonist
pharmaceutical product
muscarinic receptor
adrenoceptor agonist
Prior art date
Application number
BRPI0918431A
Other languages
English (en)
Inventor
Alan John Nadin
Barbara Giuseppina Avitabile
Nicholas Charles Ray
Original Assignee
Astrazeneca Ab
Pulmagen Therapeutics Synergy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Pulmagen Therapeutics Synergy filed Critical Astrazeneca Ab
Publication of BRPI0918431A2 publication Critical patent/BRPI0918431A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0918431A 2008-08-12 2009-08-11 produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista de beta-2-adrenoceptor. BRPI0918431A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0814728.2A GB0814728D0 (en) 2008-08-12 2008-08-12 New combination
PCT/SE2009/050925 WO2010019098A1 (en) 2008-08-12 2009-08-11 Pharmaceutical product comprising a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist

Publications (1)

Publication Number Publication Date
BRPI0918431A2 true BRPI0918431A2 (pt) 2015-11-24

Family

ID=39790659

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918431A BRPI0918431A2 (pt) 2008-08-12 2009-08-11 produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista de beta-2-adrenoceptor.

Country Status (12)

Country Link
US (1) US20110245293A1 (pt)
EP (1) EP2323656A4 (pt)
JP (1) JP2011530587A (pt)
KR (1) KR20110045051A (pt)
CN (1) CN102202664A (pt)
AU (1) AU2009282520A1 (pt)
BR (1) BRPI0918431A2 (pt)
CA (1) CA2733523A1 (pt)
GB (1) GB0814728D0 (pt)
MX (1) MX2011001579A (pt)
RU (1) RU2011105463A (pt)
WO (1) WO2010019098A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
EA017627B1 (ru) 2008-05-13 2013-01-30 Астразенека Аб Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
CA2733449A1 (en) * 2008-08-12 2010-02-18 Astrazeneca Ab 2-hydroxy-ethanesulfonate salt
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
WO2016009253A1 (en) * 2014-07-16 2016-01-21 Anil Mishra Recombinant interleukin-15 is a therapeutic agent for the treatment of airway hyperactivity, resistance (obstruction) and fibrosis in chronic asthma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
PT1891974E (pt) * 2004-05-31 2010-09-27 Almirall Sa Combinações que compreendem agentes anti-muscarínicos e inibidores de pde4
TW200738658A (en) * 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) * 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
WO2008023157A1 (en) * 2006-08-21 2008-02-28 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as m3-receptor modulators
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702385D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
EP2121688A1 (en) * 2007-02-15 2009-11-25 Argenta Discovery Ltd Heterocyclic derivatives as m3 muscarinic receptors

Also Published As

Publication number Publication date
KR20110045051A (ko) 2011-05-03
CN102202664A (zh) 2011-09-28
GB0814728D0 (en) 2008-09-17
MX2011001579A (es) 2011-04-27
AU2009282520A1 (en) 2010-02-18
EP2323656A1 (en) 2011-05-25
EP2323656A4 (en) 2012-05-30
RU2011105463A (ru) 2012-09-20
JP2011530587A (ja) 2011-12-22
WO2010019098A1 (en) 2010-02-18
US20110245293A1 (en) 2011-10-06
CA2733523A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
LTC2379069I2 (lt) S1p receptoriaus agonisto dozavimas
BRPI0919539A2 (pt) antagonistas de receptor de opioide periférico e empregos dos mesmos
PT2317852E (pt) Formulações farmacêuticas contendo ligandos de recetor de dopamina
DK2692341T3 (da) Misbrugs-resistent lægemiddelformulering
BRPI1014877A8 (pt) compostos diamida tendo antagonista do receptor muscarínico e atividade agonista do receptor b2 adrenérgico.
DK2252581T3 (da) Kappa-selektiv opioidreceptorantagonist
BRPI0821683A2 (pt) Medicamento compreendendo um agonista parassimpatético e um antagonista simpatético ou agonista simpatético
DK2274030T4 (da) Lægemiddelafgivelsesanordning
BRPI0913008A2 (pt) dispositivo de administração de medicação
EP2350060A4 (en) Melanocortin receptor AGONISTS
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
DK2381986T3 (da) Lægemiddeladministrationsanordning
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
BRPI0810926A2 (pt) Antagonista de crig
PL2379086T3 (pl) Preparat farmeceutyczny
BRPI0820805A2 (pt) Antagonista do receptor de mineralocorticóides derivados da 6h-di-benzo[b,e]oxepina
BRPI0921654A2 (pt) formulação farmacêutica
BRPI0806966A2 (pt) Combinação de um antagonista de receptor muscarínico e um agonista beta-2-adrenoceptor
BRPI0817833A2 (pt) Composição farmacêutica antimalárica
IL198780A0 (en) Pharmaceutical formulation comprising neurokinin antagonist
BRPI0922423A2 (pt) dispositivo de liberação de fármaco
BR112012002445A2 (pt) uso de um agonista do receptor 4 de melanocortina.
BRPI0918431A2 (pt) produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista de beta-2-adrenoceptor.
BRPI0912657A2 (pt) produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor
BRPI0912656A2 (pt) formulação farmacêutica sólida

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]